GlassScriptPhysician profile
George H Wathen
NPI 1861453284
$8,431.74
in general payments reported to CMS, 2019-2025
62 companies · $644 in 2025
The $644 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $1,769 · 2021: $2,175 · 2022: $1,126 · 2023: $1,056 · 2024: $711 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366 · Education: $45.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,366.10 |
| Education | $45.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $866.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $769.81 | 2019-2024 | Farxiga, Airsupra, Fasenra |
| Pfizer INC. | $710.48 | 2019-2025 | |
| Abbvie INC. | $685.42 | 2019-2024 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $672.16 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $483.09 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Amgen INC. | $423.49 | 2019-2024 | Evenity, Prolia, Repatha |
| E.R. Squibb & Sons, L.L.C. | $391.53 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.29 | 2020-2024 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $219.15 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $162.99 | 2019-2022 | |
| Allergan, INC. | $160.05 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $160.02 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $159.34 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $152.15 | 2023-2025 | Gemtesa |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Wathen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.